Evidence map›Paper›PMID 40322855›Full record

ArticleBritish journal of haematology2025

A phase 2 study of single agent ibrutinib for first-line treatment of chronic graft-versus-host disease: A new paradigm and lessons learned.

Najla El Jurdi, Noa G Holtzman, Rania Hishmeh, Alain Mina, Eduard Schulz, Anita Stokes, Grace Li, Keith T Schmidt, William D Figg, Nicholas Micheletti and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [First-line treatment for chronic graft-versus-host disease: a real-world study].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Najla El JurdiImmune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-9268-9655
Noa G HoltzmanImmune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Rania HishmehImmune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Alain MinaImmune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Eduard SchulzImmune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Anita StokesImmune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Grace LiImmune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Keith T SchmidtClinical Pharmacology Program, National Cancer Institute, Bethesda, Maryland, USA.
William D FiggClinical Pharmacology Program, National Cancer Institute, Bethesda, Maryland, USA.
Nicholas MichelettiOffice of Collaborative Biostatistics, CCR, NCI, NIH, Bethesda, Maryland, USA.
Jacqueline W MaysOral Immunobiology Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA.
Edward W CowenDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA.
Steven Z PavleticImmune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Iskra PusicWashington University School of Medicine, St Louis, Missouri, USA.

Funding

Clinical PharmacologyZ01BC010627 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2004 to 2008
$938k
Pharmacokinetic and Pharmacodynamic Modeling of Anticancer AgentsZ01BC010548 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2003 to 2008
$815k
Sample Processing and Analytical Methods Development for New Anticancer AgentsZ01SC006536 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 1997 to 2008
$731k
Using Clinical Pharmacology Principles to Develop New Anticancer TherapiesZ01SC006537 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 1997 to 2008
$379k
Intramural NIH HHS Z01 BC010548Intramural NIH HHS Z01 BC010627Intramural NIH HHS Z01 SC006536Intramural NIH HHS Z01 SC006537This work was supported by funding from the Intramural Research Program, National Institutes of Health, Center for Cancer Research, National Cancer Institute, Center for Cancer Research, also through a Collaborative Research Agreement between Pharmacyclics and the Center for Cancer Research.
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

allogeneic haematopoietic cell transplantationchronic graft‐versus‐host diseasefront‐line treatmentibrutinib

Identifiers

PMID40322855
PMCPMC12302506

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.